| 開催日 | 2019年3月22日(金) |
|---|---|
| 開催地 | 兵庫県 |
The cell and gene therapy market has experienced an immense growth driven by recent landmark approvals. As of the end of 2018, there were over one thousand clinical trials in this field worldwide, with many of them showing remarkable therapeutic efficacy. There is an overwhelming need for enabling technologies in manufacturing to allow for production at scale to meet both clinical and commercial market demand. These advancements in technology will be needed to drive down costs of goods without compromising achieving consistent product of highest quality and safety. In our discussion, we will outline the specific challenges developers of these groundbreaking therapies are facing and highlight solutions which will help overcome some of the issues faced by the industry. In particular, we will focus on innovative platforms in viral vector manufacturing, and well as autologous and allogeneic cell therapy manufacturing.
日時: 3月22日(金) 12:10 – 1:00 pm
会場: 神戸国際会議場 第9会場「会議室502」
演者: Minh Hong, Ph.D., Associate Director, Commercial Development
Head, Allogeneic Cell Therapy, Lonza Pharma & Biotech
座長：中野 峰弘 Takahiro Nakano, DVM, PhD, MBA
ロンザジャパン株式会社 受託製造開発事業部
シニア・セールス・マネージャー APAC セル・セラピー/ジーン・セラピー
*本プレゼンテーションの言語は英語になります。
*本プレゼンテーショは 第18回日本再生医療学会総会の共催学術セミナー 20（ランチョンセミナー）です。
本セミナーの聴講には整理券が必要です。
現在、第18回日本再生医療学会会期中の面談のご要望を承っております。面談をご希望中のお客様はメールもしくはお電話にてお気軽にお問合せ下さい。
